Search Results

Ask a specific question about this device

The UroSurge SpiraFlo Ureteral Stent has no holes in the walls along the side of the stent. This is in addition to the fact that it will be used for temporary drainage from the ureteropelvic junction to the bladder. Double pigtail stents have been employed to relieve obstruction in a variety of benign, malignant, and post-traumatic conditions. These stents may be placed using endoscopic, percutaneous, or even surgical techniques. These stents must not remain indwelling for more than 29 days. This product is intended for one-time use only. If the patient's status permits, the stent may be replaced with a new stent.

The UroSurge SpiraFlo Ureteral Stent has no holes in the walls along the side of the stent. This is in addition to the fact that it will be used for temporary drainage from the ureteropelvic junction to the bladder. Double pigtail stents have been employed to relieve obstruction in a variety of benign, malignant, and post-traumatic conditions. These stents may be placed using endoscopic, percutaneous, or even surgical techniques. These stents must not remain indwelling for more than 29 days. This product is intended for one-time use only. If the patient's status permits, the stent may be replaced with a new stent.

I am sorry, but the provided text does not contain the information required to describe the acceptance criteria and the study that proves the device meets the acceptance criteria. The document is an FDA 510(k) clearance letter for the UroSurge SpiraFlo Ureteral Stent, primarily outlining its substantial equivalence to a predicate device and its indications for use. It does not detail specific acceptance criteria, study methodologies, or performance results.

Ask a specific question about this device

The UroSurge SpiraStent Plus™ Ureteral Stent, has a reinforcing filament which increases its tensile strength, thereby minimizing the probability of the stent breaking during removal. This is in addition to the fact that it will be used for temporary drainage from the ureteropelvic junction to the bladder. Double pigtail stents have been employed to relieve obstruction in a variety of benign, malignant, and post-traumatic conditions. These stents may be placed using endoscopic, percutaneous, or even surgical techniques. The duration of the placement of these stents must not remain indwelling more than twenty-nine (29) days. This product is intended for one-time use only. If the patient's status permits, the stent may be replaced with a new stent.

The UroSurge SpiraStent Plus™ Ureteral Stent, has a reinforcing filament which increases its tensile strength, thereby minimizing the probability of the stent breaking during removal.

This FDA 510(k) summary for the UroSurge SpiraStent™ PLUS is a notification of intent to market and does not contain information on acceptance criteria, a study proving the device meets criteria, or details regarding ground truth, sample sizes, or expert qualifications for performance evaluation. It primarily focuses on demonstrating substantial equivalence to a legally marketed predicate device.

Therefore, I cannot extract the requested information from the provided document. The document confirms that the device is substantially equivalent for its intended use, which is for temporary drainage from the ureteropelvic junction to the bladder, with an indwelling duration not exceeding twenty-nine (29) days. It also highlights an added feature of a reinforcing filament to minimize breakage during removal. This regulatory document does not typically include detailed performance study data against specific acceptance criteria.

Ask a specific question about this device

The UroSurge FilaStent TM Ureteral Stent, has a reinforcing filament which increases its tensile strength, thereby minimizing the probability of the stent breaking during removal. This is in addition to the fact that it will be used for temporary drainage from the ureteropelvic junction to the bladder. Double pigtail stents have been employed to relieve obstruction in a variety of benign, malignant, and post-traumatic conditions. These stents may be placed using endoscopic, percutaneous, or even surgical techniques. The duration of the placement of these stents must not remain indwelling more than twenty-nine (29) days. This product is intended for one-time use only. If the patient's status permits, the stent may be replaced with a new stent.

UroSurge FilaStent™ Ureteral Stent

The provided text is a 510(k) premarket notification approval letter for the UroSurge FilaStent Ureteral Stent. This document details the FDA's decision regarding the device's substantial equivalence to previously marketed devices. However, it does not contain any information about acceptance criteria, device performance studies, sample sizes, expert qualifications, adjudication methods, MRMC studies, standalone performance, or training set details.

Therefore, I cannot fulfill your request to describe the acceptance criteria and the study that proves the device meets them, as this information is not present in the provided text.

Ask a specific question about this device